Correlation Between Can Fite and ImmuCell

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Can Fite and ImmuCell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Can Fite and ImmuCell into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Can Fite Biopharma and ImmuCell, you can compare the effects of market volatilities on Can Fite and ImmuCell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Can Fite with a short position of ImmuCell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Can Fite and ImmuCell.

Diversification Opportunities for Can Fite and ImmuCell

0.12
  Correlation Coefficient

Average diversification

The 3 months correlation between Can and ImmuCell is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Can Fite Biopharma and ImmuCell in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ImmuCell and Can Fite is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Can Fite Biopharma are associated (or correlated) with ImmuCell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ImmuCell has no effect on the direction of Can Fite i.e., Can Fite and ImmuCell go up and down completely randomly.

Pair Corralation between Can Fite and ImmuCell

Given the investment horizon of 90 days Can Fite Biopharma is expected to generate 1.71 times more return on investment than ImmuCell. However, Can Fite is 1.71 times more volatile than ImmuCell. It trades about 0.03 of its potential returns per unit of risk. ImmuCell is currently generating about 0.02 per unit of risk. If you would invest  154.00  in Can Fite Biopharma on December 28, 2024 and sell it today you would earn a total of  0.00  from holding Can Fite Biopharma or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Can Fite Biopharma  vs.  ImmuCell

 Performance 
       Timeline  
Can Fite Biopharma 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Can Fite Biopharma are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Can Fite may actually be approaching a critical reversion point that can send shares even higher in April 2025.
ImmuCell 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in ImmuCell are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound fundamental indicators, ImmuCell is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.

Can Fite and ImmuCell Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Can Fite and ImmuCell

The main advantage of trading using opposite Can Fite and ImmuCell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Can Fite position performs unexpectedly, ImmuCell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmuCell will offset losses from the drop in ImmuCell's long position.
The idea behind Can Fite Biopharma and ImmuCell pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Complementary Tools

Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
CEOs Directory
Screen CEOs from public companies around the world
Transaction History
View history of all your transactions and understand their impact on performance